Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early oxybutynin treatment for boys with posterior urethral valves
2024-515844-22-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of oxybutynin in congenital posterior urethral valves (PUV) (2 arms), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Composite treatment success at 9 months after inclusion. Planned start Sep 2020; status: authorised.
02
Drugs
oxybutynin
03
Conditions
congenital posterior urethral valves (PUV)
Beyond the preview
Go deeper on 2024-515844-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515844-22-00.